Answers are grounded in this paper and cite their sources.
Demonstrates effective gene expression targeting in retinal ganglion cells, indicating potential for advanced gene therapies.
The Nrn1-PEC enables efficient and injury-resilient gene expression in RGCs, addressing a key limitation in cell-specific targeting. This AAV-incorporated PEC offers a robust platform for evaluating neuroprotective interventions and accelerates the translational development of gene therapies for glaucoma and other optic neuropathies.
No takes yet. Share an insight, caveat, or question.
Talla et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: